Jazz Pharmaceuticals plc Stock
Jazz Pharmaceuticals plc Stock
We can see a decrease in the price for Jazz Pharmaceuticals plc. Compared to yesterday it has lost -€4.300 (-2.540%).
With 35 Buy predictions and not a single Sell prediction Jazz Pharmaceuticals plc is an absolute favorite of our community.
With a target price of 176 € there is a slightly positive potential of 6.31% for Jazz Pharmaceuticals plc compared to the current price of 165.55 €.
Pros and Cons of Jazz Pharmaceuticals plc in the next few years
Pros
?
W********* I********* f** t** n*** y****
?
S********** s********
?
M***** P*******
Cons
?
G***** c******* t* c**********
?
B****
?
C******** o* t** e**********
Tell us your opinion to access the 'Wisdom of the Crowds'
Performance of Jazz Pharmaceuticals plc vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| Jazz Pharmaceuticals plc | -2.540% | 2.191% | 3.404% | 81.803% | 14.647% | 25.941% | 20.751% |
| Repligen Corp. | -1.220% | -2.538% | -9.746% | -0.080% | -29.386% | -33.159% | -41.972% |
| Opko Health Inc. | 3.160% | 4.466% | 1.449% | -15.401% | -10.108% | -22.737% | -71.944% |
| Amicus Therapeutics Inc. | 0.290% | 0.123% | 0.123% | 98.618% | 1.792% | 20.941% | 58.636% |
Comments
Jazz Pharmaceuticals (JAZZ) had its price target raised by Piper Sandler from $219.00 to $232.00. They now have an "overweight" rating on the stock.
Show more
Ratings data for JAZZ provided by MarketBeat
Jazz Pharmaceuticals (JAZZ) had its "overweight" rating reaffirmed by Barclays PLC.
Show more
Ratings data for JAZZ provided by MarketBeat
Jazz Pharmaceuticals (JAZZ) is now covered by Barclays PLC. They set an "overweight" rating and a $224.00 price target on the stock.
Show more
Ratings data for JAZZ provided by MarketBeat